NCT00605085View on ClinicalTrials.gov

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

PHASE3CompletedINTERVENTIONAL
Enrollment

2,675

Participants

Timeline

Start Date

October 31, 2005

Study Completion Date

November 30, 2006

Conditions
Japanese Encephalitis
Interventions
BIOLOGICAL

Japanese Encephalitis purified inactivated vaccine (IC51)

IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28

BIOLOGICAL

Placebo

Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28

All Listed Sponsors
lead

Valneva Austria GmbH

INDUSTRY